Τίτλος:
Heterogeneous HER2 Gene Amplification Impact on Patient Outcome and a
Clinically Relevant Definition
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Heterogeneous expression or amplification is a challenge to HER2
diagnostics. A guideline defines heterogeneity as the presence of
between 5% and 50% cells with HER2/CEP17 ratios of more than 2.20. We
audited the frequency of such cells and their clinical impact in the
results from 2 pathology laboratories combined with data from the TEAM
[Tamoxifen vs Exemestane Adjuvant Multicentre] pathology study. HER2
reports were scanned and the percentages of amplified cells reported.
Of 6,461 eligible cases, 754 (11.7%) exhibited 50% or more cells with
ratios of more than 2.20, which is “amplified” by College of
American Pathologists guidelines. Of the cases, 2,166 (33.5%) exhibited
more than 5% but less than 50% of cells with HER2/CEP17 ratios of more
than 2.20, or “heterogeneous amplification.” No prognostic impact
was observed when fewer than 30% of cells exhibited ratios of more than
2.20. All amplified cases with 30% to 50% of cells with ratios more
than 2.20 were identified as such by United Kingdom guidelines.
The percentage of tumor cells with HER2/CEP17 ratios more than 2.20 does
not identify cases with heterogeneous amplification or poor outcome. A
modified approach for identification of true heterogeneous amplification
is suggested.
Συγγραφείς:
Bartlett, Alastair I.
Starcyznski, Jane
Robson, Tammy and
MacLellan, Alex
Campbell, Fiona M.
van de Vekle, Cornelis J. H.
and Hasenburg, Annette
Markopoulos, Christos
Seynaeve, Caroline
and Rea, Daniel
Bartlett, John M. S.
Περιοδικό:
AMERICAN JOURNAL OF CLINICAL PATHOLOGY
Εκδότης:
OXFORD UNIV PRESS INC
Λέξεις-κλειδιά:
HER2; Amplification; Breast; Heterogeneity
DOI:
10.1309/AJCP0EN6AQMWETZZ
